Literature DB >> 12458896

False elevation of serum CA-125 level caused by human anti-mouse antibodies.

Roger L Bertholf1, Laura Johannsen, Benrubi Guy.   

Abstract

Discordant results were observed for serum CA-125 (carbohydrate antigen-125) assays in a patient who was monitored for recurrence of ovarian cancer. Serum CA-125 levels in this patient were normal when measured in one laboratory, but >5-times the upper limit of normal (35 U/mL) when measured in another laboratory. Both laboratories used dual antibody heterogeneous immunoassays, but from different manufacturers. Cross-linking heterophilic antibodies were suspected as a cause of the discrepancy, but the interference was not alleviated after 10-fold dilution. Assay of the patient's serum for human anti-mouse antibodies was positive, but only slightly above the reference range. Addition of blocking antibodies eliminated the interference, showing that human anti-mouse antibodies were the cause of the discrepant CA-125 results. These findings indicate that relatively low concentrations of human anti-mouse antibodies can cause significant interference in two-site immunoassays.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458896

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  4 in total

1.  Rheumatoid arthritis: correlation between rheumatoid factor levels and CA-125 tumour marker elevation.

Authors:  Nicolas Tsavaris; Clio P Mavragani; Dimitrios Pikazis; Pikazis Dimitrios
Journal:  Ann Rheum Dis       Date:  2007-07       Impact factor: 19.103

2.  Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Authors:  Raffit Hassan; Charles Schweizer; Kun F Lu; Barbara Schuler; Alan T Remaley; Susan C Weil; Ira Pastan
Journal:  Lung Cancer       Date:  2009-09-09       Impact factor: 5.705

3.  Diminution of falsely elevated tumour markers following immunosuppression for systemic lupus erythematosus with neurological involvement.

Authors:  Jonathan Bevan; Michael Richardson
Journal:  BMJ Case Rep       Date:  2016-04-05

Review 4.  Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.

Authors:  Charlotte S Marcus; G Larry Maxwell; Kathleen M Darcy; Chad A Hamilton; William P McGuire
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.